Stay updated with breaking news from Clinical Development Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Jul 27, 2023--
Participants in SURMOUNT-3, after 12 weeks of intensive lifestyle intervention, achieved an additional 21.1% mean weight loss with tirzepatide for a total mean weight loss of 26.6% from study entry...
‒ Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema (DME) – ‒ Real-world data reinforce that first-line
‒ Late-breaking post-hoc data indicate Vabysmo leads to less fibrosis, which may negatively impact vision, than aflibercept in people with diabetic macular edema (DME) –‒ Real-world data reinforce that first-line Vabysmo use improves outcomes and extends treatment intervals rapidly during the first four months for p...
First and only FLT3 inhibitor approved across three phases of AML treatment based on QuANTUM-First results demonstrating VANFLYTA added to chemotherapy improved overall survival Third innovative...